Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
As a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Th...
Guardado en:
Autores principales: | Yong Jiang, Tao Han, Zhi-Guang Zhang, Man Li, Feng-Xiang Qi, Ying Zhang, Ying-Lan Ji |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2dc2abff5b64dabb16e2113912d964a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018) -
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
por: Gwyneth Shook Ting Soon, et al.
Publicado: (2021) -
Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults
por: Huan-Huan Yang, et al.
Publicado: (2021) -
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Tae Hyung Kim, et al.
Publicado: (2021) -
Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
por: Huang Z, et al.
Publicado: (2017)